Business Context and Reporting Period
Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002
Business Overview: Regeneron is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for serious medical conditions. The company has not yet generated revenue from the commercialization of its own product candidates. Its primary revenue sources are contract research and development (R&D) agreements, contract manufacturing, and investment income. Key product candidates include AXOKINE (obesity), IL-1 Trap (rheumatoid arthritis), VEGF Trap (cancer), and IL-4/13 Trap (asthma/allergies).
Key Financial Metrics (Year Ended Dec 31, 2002)
| Metric | 2002 | 2001 |
|---|---|---|
| Total Revenue | $21.99 million | $21.97 million |
| Net Loss | $(124.38) million | $(76.18) million |
| Net Loss Per Share (Basic/Diluted) | $(2.83) | $(1.81) |
| Operating Expenses | $143.94 million | $107.66 million |
| Research & Development Expenses | $124.93 million | $91.54 million |
| Cash & Cash Equivalents | $80.08 million | $247.39 million |
| Total Cash, Securities & Restricted Securities | $295.25 million | $438.38 million |
| Long-Term Debt (Convertible Notes) | $200.00 million | $200.00 million |
| Stockholders' Equity | $145.98 million | $266.36 million |
Material Changes vs. Prior Period
- Revenue Stability: Total revenue remained flat at approximately $22.0 million. Contract manufacturing revenue increased to $11.1 million (from $9.9 million) due to a non-recurring $1.0 million payment from Merck. Contract R&D revenue decreased slightly to $10.9 million (from $12.1 million) as revenue from the Amgen-Regeneron partnership declined following the completion of studies.
- Increased Operating Loss: Net loss widened significantly to $124.4 million from $76.2 million. This was driven by a 36% increase in R&D expenses to $124.9 million, primarily due to the expansion of the Phase III clinical program for AXOKINE and the initiation of the Phase II program for IL-1 Trap.
- Interest Expense Surge: Interest expense jumped to $11.9 million from $2.7 million due to the issuance of $200 million in convertible senior subordinated notes in October 2001 (5.5% interest rate).
- Cash Position: Cash and cash equivalents decreased by approximately $167 million to $80.1 million, reflecting significant operating cash outflows ($110.5 million) and capital expenditures ($34.4 million) for facility expansions.
Guidance, Outlook, and Material Events
Recent Developments (Post-Period)
- AXOKINE Phase III Results (March 2003): Preliminary results showed statistical significance in weight loss compared to placebo. However, efficacy was limited by the development of antibodies in many subjects after three months. Subjects who did not develop antibodies achieved significantly greater weight loss (12.6 lbs vs. 4.5 lbs for placebo).
- Novartis Collaboration (March 2003): Entered into a Collaboration, License, and Option Agreement with Novartis Pharma AG for the IL-1 Trap. Regeneron received a $27.0 million up-front payment and Novartis purchased $48.0 million of Regeneron common stock. Regeneron may receive up to $275.0 million in milestone payments.
Outlook and Risks
- Liquidity: Management believes existing capital resources will fund operations through mid-2004. The company expects to incur approximately $50 million in capital expenditures in 2003.
- Key Risks:
- Antibody Formation: Development of neutralizing antibodies against protein therapeutics (observed in AXOKINE trials) could limit efficacy.
- Clinical Trial Failure: High risk of failure in clinical trials for safety or efficacy.
- Regulatory Approval: No products have received FDA approval; commercialization is years away.
- Competition: Intense competition in obesity, rheumatoid arthritis, and cancer markets from established pharmaceutical companies.
Investor Verification Checklist
- AXOKINE Antibody Data: Verify the long-term implications of antibody formation on the commercial viability of AXOKINE and the success of the Pegylated AXOKINE program.
- Novartis Deal Terms: Review the specific milestones required to earn the potential $275 million in payments and the profit-sharing structure for the IL-1 Trap.
- Cash Burn Rate: Monitor the rate of cash consumption against the projected runway to mid-2004, given the high R&D spend and lack of product revenue.
- Convertible Notes: Assess the impact of the $200 million convertible debt (maturing 2008) on future dilution if the stock price exceeds the conversion price ($30.25).
- Merck Contract: Confirm the stability of the contract manufacturing revenue stream with Merck, which is a significant portion of current revenue.